-transparent.png){kind=logo}
Six weeks after receiving a total dose of 20 units of bleomycin sulfate as part of BACOP therapy for non-Hodgkin's lymphoma, our patient had dyspnea and cough with marked hypoxemia. Open lung biopsy established the diagnosis of "bleomycin lung," confirmed by postmortem examination. Fatal bleomycin pulmonary toxicity can develop with any dosage, and routine tests are incapable of detecting early, reversible toxicity.
Related Publications
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
November 1999,
American journal of hematology,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
September 1995,
The Journal of rheumatology,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
January 1986,
Cancer chemotherapy and pharmacology,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
August 1994,
Radiology,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
June 1987,
Journal of surgical oncology,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
March 1976,
JAMA,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
December 2022,
International immunopharmacology,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
October 1977,
Schweizerische medizinische Wochenschrift,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
December 1987,
Cancer,
D E Bechard, and
R P Fairman, and
G G DeBlois, and
C T Via
June 1973,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
